{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037625","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.132725+00:00","generated_at":"2026-06-21T22:00:08.773762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Achieve Life Sciences Q3 net loss $13.1M; Phase 3 ORCA-3 and Phase 2 ORCA-V1 enrollment completed","bullets":["Net loss of $13.1M for Q3 2022; operating expenses $12.6M; cash and restricted cash $18.2M as of Sept 30, 2022.","Phase 3 ORCA-3 trial of cytisinicline enrolled 750 adult smokers; topline data expected Q2 2023.","Phase 2 ORCA-V1 trial of cytisinicline in 150 e-cigarette users completed enrollment early; topline data expected Q2 2023.","Sopharma completed new API purification suite for cytisinicline with >€3M cost, expanding global production capacity.","9,710,747 shares outstanding as of Nov 10, 2022; no revenue (pre-commercial stage)."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037625","json":"https://secwatch.observer/filing/0001564590-22-037625.json","markdown":"https://secwatch.observer/filing/0001564590-22-037625.md","text":"https://secwatch.observer/filing/0001564590-22-037625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/0001564590-22-037625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/achv-8k_20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:00:08.773762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"125c80e2270018bfe09f5546385e2b2644d29e77","claim":"ACHIEVE LIFE SCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $13.1 million.","evidence_excerpt":"Total net loss for the three and nine months ended September 30, 2022 was $13.1 million and $31.1 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/0001564590-22-037625-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$13.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}